Clinical trial ELDERLY
Pertuzumab + trastuzumab (PH) versus PH plus metronomic chemotherapy (PHM) in the elderly HER2+ metastatic breast cancer population who may continue on T-DM1 alone following disease progression while on PH / PHM: an open-label multicenter randomized phase II selection trial of the EORTC Elderly Task Force and Breast Cancer Group
Cancers | |
---|---|
Organ | Breast |
Trial status | Trial closed |
Investigator | |
Trial type |
Interventional with experimental drug
|
Phase | Trial phase 2 |
Academic trial | Non |
Sponsor | EORTC |
EudraCT Identifier | 2011-00634-232 |
ClinicalTrials.gov | https://clinicaltrials.gov/ct2/show/NCT01597414 |
Inclusion criteria | HER2+. Age Superior to 70 years old |
Last update |